Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
